YieldBasis (YB) 24-hour volatility reaches 40.5%: Trading volume surges 173% driving price rebound
Bitget Pulse2026/04/18 05:20Volatility Brief
In the past 24 hours, YB's price rebounded from a low of $0.1206 to a high of $0.1694, currently quoted at $0.1687, with a price fluctuation amplitude of 40.5%. Trading volume surged by 173.7% to $26.85 million, significantly higher than the previous day. Net outflows from CEX amounted to about $212,000, while DEX saw a slight net inflow of $4,025.
Brief Analysis of the Cause of the Volatility
- Trading volume spiking by 173.7% to $26.85 million was mainly driven by speculative buying, with no official announcements or major news events.
- Influenced by the Q1 earnings report released one day ago, which showed the protocol gained $12 million in fees from BTC volatility and TVL reached $196 million.
- No significant whale activity or on-chain anomalies observed.
Market View and Outlook
Main sentiment in the X community is short-term bullish, with active trading signals and bulls entering from $0.1164, hitting multiple TPs at $0.138 and beyond with profits exceeding 900%; some views believe the move is pure momentum-driven with volume up +419%, but warn of potential sell pressure from upcoming token unlocks and risks of a rapid pullback, suggesting to wait for support confirmation.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, and is for informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
Crypto prices
More
